SOHO 2025 | Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
Mhairi Copland, MB ChB, PhD, University of Glasgow, Glasgow, UK, comments on the challenges of co-targeting in chronic myeloid leukemia (CML), highlighting the need to balance efficacy with minimizing additional side effects, particularly in patients who have achieved remission. Dr Copland emphasizes the importance of developing therapies that can eliminate the need for future stem cell transplant, and notes that understanding the bone marrow microenvironment and immune system may hold the key to improving responses in the future. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
